Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLX-200 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PLX-200 | DRUG | 15 mg/mL oral solution of experimental drug |
| Placebo | DRUG | Taste and color-matched drug-free solution |
PLX-200 is an investigational small molecule being developed for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3), a rare genetic disorder. It is currently in Phase 3 clinical development and has not yet been approved by the FDA.
PLX-200 is being developed by Polaryx Therapeutics, Inc., a biopharmaceutical company. The company's common stock trades under the ticker symbol PLYX on the stock market.
PLX-200 is currently in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Fast Track designation by the FDA for its intended indication.
PLX-200 is being evaluated in a Phase 3 clinical trial with the identifier NCT04637282. This trial is designed to assess the safety, tolerability, and efficacy of PLX-200 in patients with CLN3, also known as Juvenile Neuronal Ceroid Lipofuscinosis. The trial is not yet recruiting and has a planned enrollment of 39 participants.
PLX-200 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available information.